Evidence map›Paper›PMID 29467679›Full record

ArticleFrontiers in psychiatry2018

The Endocannabinoid System across Postnatal Development in Transmembrane Domain

Rose Chesworth, Leonora E Long, Cynthia Shannon Weickert, Tim Karl

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Early Consumption of Cannabinoids: From Adult Neurogenesis to Behavior.International journal of molecular sciences · 2021
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Rose ChesworthSchool of Medicine, Western Sydney University, Campbelltown, NSW, Australia.
Leonora E LongSchizophrenia Research Institute, Sydney, NSW, Australia.
Cynthia Shannon WeickertSchizophrenia Research Institute, Sydney, NSW, Australia.
Tim KarlSchool of Medicine, Western Sydney University, Campbelltown, NSW, Australia.
Western Sydney University · AUNeuroscience Research Australia · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of cannabis is a well-established component risk factor for schizophrenia, particularly in adolescent individuals with genetic predisposition for the disorder. Alterations to the endocannabinoid system have been found in the prefrontal cortex of patients with schizophrenia. Thus, we assessed whether molecular alterations exist in the endocannabinoid signalling pathway during brain development in a mouse model for the schizophrenia risk gene

Indexed as

cannabinoid receptor 1developmentdiacylglycerol lipase alphaendocannabinoid systemmonoglyceride lipaseneuregulin 1schizophreniaα/β-hydrolase domain-containing 6

Identifiers

PMID29467679
PMCPMC5808294
OpenAlexW2789646242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.